Search Results
Results found for "imposter syndrome"
- Knowing When to Walk, Knowing When to Run: Lessons from the Bench
Watch Episode 166 Early-career scientists often wrestle with impostor syndrome. Imposter Syndrome and Finding Your Place Ben shares the moment he realized he mattered, when he was science rewards the bold. _________________ Keyword Cloud: GPCR online course, early-career scientists, imposter syndrome, GPCR podcast, neuroma model
- Inversago Pharma Announces Dosing of First Participant with Metabolic Syndrome in Phase 1B ...
March 2022 Inversago Pharma Announces Dosing of First Participant with Metabolic Syndrome in Phase 1B portfolio of CB1 inverse agonists, announced today the dosing of the first participant with metabolic syndrome pharmacokinetics and safety profile of Inversago’s lead molecule, INV-202, on a targeted population with metabolic syndrome
- Characterization of a new WHIM syndrome mutant reveals mechanistic differences in regulation of ...
Characterization of a new WHIM syndrome mutant reveals mechanistic differences in regulation of the chemokine receptor CXCR4 WHIM syndrome is a rare immunodeficiency disorder that is characterized by warts, hypogammaglobulinemia Here, we report on a new WHIM syndrome mutation that results in a frame shift within the codon for Ser339 S339fs5) and compare the properties of S339fs5 with wild type CXCR4 and a previously identified WHIM syndrome Taken together, these studies identify a new WHIM syndrome mutant, CXCR4-S339fs5, that promotes enhanced
- Anosmin 1 N-terminal domains modulate prokineticin receptor 2 activation by prokineticin 2
August 2022 "The X-linked form of Kallmann syndrome (KS), characterized by hypogonadotropic hypogonadism
- Deficiency of β-arrestin2 alleviates apoptosis through GRP78-ATF6-CHOP signaling pathway in ...
of β-arrestin2 alleviates apoptosis through GRP78-ATF6-CHOP signaling pathway in primary Sjögren's syndrome The etiology of primary Sjögren's syndrome (pSS) remains unknown, and there is no ideal drug for the In this study, we established an experimental Sjögren's syndrome (ESS) mouse model to elucidate the molecular
- What If the Most Important Part of Your Drug Isn’t What It Binds—But What It Does?
Picture this: two compounds bind to the same receptor. One sparks a firestorm of cellular activity. The other? Silence. Why? The answer lies in a misunderstood property called efficacy—the power of a drug to trigger a response after binding. In Terry Kenakin’s latest lesson, you’ll uncover why efficacy is the unsung hero of drug discovery and how its effects depend entirely on the biological system it’s tested in. This isn’t just a theory class. Terry walks you through real-world experiments, decades of receptor pharmacology wisdom, and the cutting-edge operational model used to quantify efficacy. You'll learn why some agonists succeed in sensitive tissues but fail elsewhere—and how this knowledge can dramatically shift your screening strategy. If you’re stuck trying to figure out why your lead compound looks promising in vitro but flops in vivo, you need this lesson. Ready to think beyond binding? 🔓 Find the lesson in Terry’s Pharmacology Vault: “Efficacy and System Sensitivity Unlock "Agonism & Efficacy" now
- Novel Driver Strength Index highlights important cancer genes in TCGA PanCanAtlas patients
September 2022 "Background Cancer driver genes are usually ranked by mutation frequency, which does not necessarily reflect their driver strength. We hypothesize that driver strength is higher for genes preferentially mutated in patients with few driver mutations overall, because these few mutations should be strong enough to initiate cancer. Methods We propose formulas for the Driver Strength Index (DSI) and the Normalized Driver Strength Index (NDSI), the latter independent of gene mutation frequency. We validate them using TCGA PanCanAtlas datasets, established driver prediction algorithms and custom computational pipelines integrating SNA, CNA and aneuploidy driver contributions at the patient-level resolution." Read more at the source #DrGPCR #GPCR #IndustryNews
- Adrenal G Protein-Coupled Receptors and the Failing Heart: A Long-distance, Yet Intimate Affair
October 2022 "Systolic heart failure (HF) is a chronic clinical syndrome characterized by the reduction Chronic human HF is characterized by several important neurohormonal perturbations, emanating from both The adrenal gland plays an important role in the modulation of cardiac neurohormonal stress because it In this review, we discuss important aspects of adrenal GPCR signaling and regulation, as they pertain
- Embark on a GPCR Adventure: Your Weekly Research Expedition! | Oct 21-27, 2024
Olfactive Biosolutions Establishes Scientific Advisory Board GLP-1s like Ozempic are among the most important Activation and Signaling A gain of function variant in RGS18 candidate for a familial mild bleeding syndrome
- CD28 and chemokine receptors: Signalling amplifiers at the immunological synapse
account the detrimental effect of mutations carried by distinct signalling proteins giving rise to syndromes
- Embark on a GPCR Adventure: Your Weekly Research Expedition! | Oct 21-27, 2024
Activation and Signaling A gain of function variant in RGS18 candidate for a familial mild bleeding syndrome
- The regulation of PKA signaling in obesity and in the maintenance of metabolic health
Variants identified in PKA subunit genes cause Cushing syndrome that is characterized by metabolic dysregulation
- The Adhesion GPCR VLGR1/ADGRV1 Regulates the Ca2+ Homeostasis at Mitochondria-Associated ER Membrane
Mutations in VLGR1 have been associated with the human Usher syndrome (USH), the most common form of
- Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in...
statistically significant and clinically meaningful 9.6-point reduction in the Positive and Negative Syndrome
- 📰 GPCR Weekly News, June 17 to 23, 2024
targeting PAR-1 G protein-coupled receptors related to autoimmunity in postural orthostatic tachycardia syndrome Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner Monlunabant by Inversago Pharma for Metabolic Syndrome
- New role of β-arrestins in MOR signaling
The opioid system is one of the most important in regulating the response to nociception, i.e. the response receptor (DOR) which are expressed throughout the central and peripheral nervous system and regulate important their pathophysiological significance in pain, addiction and depression opioid receptors represent important study of the different signal transductions triggered by the opioid-receptor interaction is of great importance Complex Persistent Opioid Dependence-an Opioid-induced Chronic Pain Syndrome.
- Focusing on the role of secretin/adhesion (Class B) G protein-coupled receptors in placental...
B) G protein-coupled receptors in placental development and preeclampsia "Preeclampsia, a clinical syndrome
- Pharmacophore-guided Virtual Screening to Identify New β 3 -adrenergic Receptor Agonists
agonists are used clinically: mirabegron 1 and vibegron 2, which are indicated for overactive bladder syndrome
- 📰 GPCR Weekly News, November 6 to November 12, 2023
more details about the speakers on the Live Talks page, and make sure to mark your calendar for this important behavior Acetate mitigates cardiac mitochondrial dysfunction in experimental model of polycystic ovarian syndrome
- 📰 GPCR Weekly News, May 6 to 12, 2024
GPCR, hear anecdotes, and get important announcements. in multiple morphogenetic events and regulation by AbdA GPCR Activation and Signaling The critical importance of the TADopathy, X-Linked Acrogigantism Thrombosis With Thrombocytopenia and Post-COVID-Vaccination Syndrome
- Chemokine receptor-targeted drug discovery: progress and challenges
mogamulizumab has also been approved in Japan and by the FDA for the treatment of mycosis fungoides or Sézary syndrome Another important aspect in CKRs targeted drug discovery is the concept of biased agonism/antagonism,
- 📰 GPCR Weekly News, April 17 to 23, 2023
regulates cardiac oxylipin balance to promote inflammation resolution in HFpEF secondary to metabolic syndrome
- 📰 GPCR Weekly News, June 3 to June 9, 2024
Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome
- Adhesion GPCR Consortium Newsletter - May 2024
typically do not sing to these since they are dear to Mexican childhood memories, and I feel like an imposter
- 📰 GPCR Weekly News, June 19 to 25, 2023
Inversago Pharma Presents Data from Phase 1b Trial of INV-202, a Peripheral CB1r Blocker for Metabolic Syndrome
- Transformative GPCR Insights: Unleash New Horizons in Science | Sep 9 - 15, 2024
in Mc4r-expressing cells is required for peripheral metabolism and systemic energy homeostasis Eiken syndrome
- 📰 GPCR Weekly News, May 22 to 28, 2023
Chemokine–Chemokine Receptor Complexes Industry News Mavorixafor reduces infection rates among patients with WHIM syndrome
- 📰 GPCR Weekly News, June 5 to 11, 2023
and Signaling Altered Signaling and Desensitization Responses in PTH1R Mutants Associated with Eiken Syndrome
- 📰 GPCR Weekly News, May 27 to June 2, 2024
Open-Label Studies For The Treatment Of Congenital Adrenal Hyperplasia (CAH) And Acth-Dependent Cushing’s Syndrome
- 📰 GPCR Weekly News, May 8 to 14, 2023
Placebo in Participants Diagnosed with WHIM Syndrome GPCR Events, Meetings, and Webinars ASPET 2023 -






